Background: Crohn's disease [CD] is known to be associated with gut microbial dysbiosis. Infliximab [IFX] is increasingly used to treat paediatric CD; however, it is not clear how the gut microbiota is modified during IFX treatment. The aim of this study was to characterise the faecal microbiota community composition in paediatric CD patients and to assess its dynamic changes during IFX therapy. Methods: A 16S rRNA sequencing approach was applied to determine the compositions of microbial communities in faecal samples. The composition and function of the faecal microbiota were compared between CD patients and healthy controls. Results: Characteristics of faecal microbiome composition in paediatric CD patients before IFX treatment were represented by a lower biodiversity, a gain in Enterococcus, and a significant loss in multiple short-chain fatty acid [SCFA]-producing bacteria, including Anaerostipes, Blautia, Coprococcus, Faecalibacterium, Lachnospira, Odoribacter, Roseburia, Ruminococcus, and Sutterella. Additionally, alterations were observed in metabolic functions of the gut microbial community in CD. IFX treatment increased the biodiversity of gut microbiota and shifted its composition as well as its functional capabilities in the paediatric CD patients toward a healthy status. However, multiple SCFA-producing taxa were not significantly expanded. The sustained response of paediatric CD patients to IFX was associated with abundance of SCFA-producing bacteria. Conclusions: A lower biodiversity with alterations in the composition and function of faecal microbial community, characterising gut microbial dysbiosis, was observed in Chinese paediatric CD patients. IFX diminished the CD-associated gut microbial dysbiosis but was deficient in increasing certain SCFA-producing taxa.
Background
Inflammatory bowel disease [IBD] refers to a group of chronic, relapsing inflammatory disorders of the gastrointestinal tract, which mainly include Crohn's disease [CD] and ulcerative colitis [UC] . 1 IBD occurs in both adults and children, with most IBD patients diagnosed among paediatric populations. 2 High incidence and prevalence of IBD are presented in North America, Northern/Western Europe, and Australia; however, new epidemiological data showed increasing incidence trends in Eastern European and Asian regions. 3 The main clinical manifestations of IBD are diarrhoea, abdominal pain, fistulas, and perianal lesions, which may affect the whole digestive tract and cause systemic symptoms. 4 The aetiology and pathogenesis of IBD are still unclear. It is assumed that IBD occurs in genetically susceptible individuals with an aberrant host immune response, which is triggered by environmental factors. 5 An alteration of the gut microbial composition, which is termed dysbiosis, has been increasingly reported in IBD over the past decade. [6] [7] [8] [9] [10] [11] Cases of IBD, especially CD, are associated with a lower microbial diversity and an imbalance in the composition of the gut microbiota [e.g. excess of aggressive versus protective commensal bacteria] compared with healthy controls. 6, 8, [12] [13] [14] Several studies showed that IBD is associated with an increase in a variety of Actinobacteria and Proteobacteria, [15] [16] [17] and low abundances in Firmicutes and Bacteroidetes. 13, 15, 18 In paediatric IBD patients, the families Coriobacteriaceae and Lachnospiraceae were decreased, and the diversity of Ruminococcaceae and Bifidobacterial populations were shown to be lower than in healthy children. 7 An increased abundance in families Enterobacteriaceae, Fusobacteriaceae, Pasteurellacaea, and Veillonellaceae, and reduced abundance in orders Bacteroidales, Clostridiales, and Erysipelotrichales, were reported in a large group of treatment-naïve, new-onset paediatric CD patients. 11 Current therapies for IBD include anti-inflammatory and immunomodulatory treatments (e.g. 5-aminosalicylates, corticosteroids, thiopurines, methotrexate, and anti-tumour necrosis factor [TNF] alpha), and microbiome modulators [e.g. antibiotics, probiotics, enteral nutrition, and faecal transplantation], which aim to achieve clinical remission and mucosal healing. 19 Infliximab [IFX], a chimeric mouse-human IgG1 monoclonal antibody against TNF-a, has been approved for treatment of paediatric IBD patients for years. 20 Clinical trials showed that administration of IFX can achieve a high clinical response rate in paediatric CD patients. 1, 20 It was also reported that IFX was more effective in obtaining mucosal healing than immunomodulators. 1, 20 In a longitudinal study of 33 adult CD patients, through exploring the changes in the gut microbiota predictive of relapse after IFX withdrawal, Rajca et al. 21 observed lower rates of Firmicutes in CD patients who relapsed compared with patients in long-term remission. In addition a bacterial profile, represented by a low rate of Faecalibacterium prausnitzii [F. prausnitzii] and a low rate of Bacteroides, is significantly predictive of CD relapse risk for up to 1 year before IFX withdrawal. 21 In the current study, we characterised the composition and function of the gut microbial community in paediatric CD, and evaluated their variations during IFX therapy. Our findings reveal that IFX corrected the dysbiosis of paediatric patients with CD, and the sustained therapeutic response was associated with the abundance of short-chain fatty acid [SCFA] -producing bacteria.
Methods

Study cohort
Eleven children with CD were recruited to the study cohort from Shanghai Children's Hospital, China, between September 2014 and December 2016. Inclusion criteria were children with a diagnosis of CD confirmed by endoscopy and histology. The diagnosis of CD was based on the Porto criteria, 22 [CRP] . Sixteen healthy controls without previous history of chronic disease were enrolled in the study by Shanghai Children's Hospital, China. None of the healthy controls had clinically relevant IBD or allergy symptoms at the time of faecal collection, and subjects who took antibiotics within 2 months before faecal collection, or had any inflammatory condition, were excluded from the study. IFX treatment was performed according to current clinical practice: 23 to administer IFX via an intravenous infusion of 5 mg/kg at Weeks 0, 2, and 6, followed by maintenance intravenous infusions every 8 weeks. Written informed consent was obtained from parents or legal guardians of all paediatric subjects. This study was approved by the Regional Ethical Review Board in Shanghai Children's Hospital.
A total of 48 faecal samples for microbiome analysis were collected from 27 participants including 11 CD patients [ 
Sample collection and genomic DNA extraction
Stool samples were collected by professional nursing staff working at Shanghai Children's Hospital, and stored at -80℃ until shipping to the HRK-biotech lab for DNA extraction and sequencing. The isolation methods comprise three steps: [1] 
16S rRNA gene sequencing analysis
Further analysis was processed in a data curation pipeline implemented in QIIME 1.9.1[http://qiime.org/]. The operational taxonomic units [OTU] were clustered using a closed-reference picking protocol with the UCLUST algorithm based on 97% nucleotide similarity, resulting in 4028 OTUs. The OTU taxonomic annotation was performed with the Greengenes 13.8 database [http://greengenes. secondgenome.com]. The OTU tables were checked for mislabelling and contamination. Samples with less than 10 000 reads filtered sequences were excluded from the analysis.
The statistical analysis was performed with SHAMAN [shaman. c3bi.pasteur.fr] based on R software [3.1.2]. 24 The normalisation of OTU counts was performed at the OTU level using a DESeq2 normalisation method. 25 A generalised linear model [GLM] was fitted and vectors of contrasts were defined, to access the significance of the differences in abundance between sample types [i.e. pre-IFX, post-IFX, and control]. The analyses were adjusted for gender, age, and body mass index [BMI] . The resulting p-values were adjusted for multiple testing according to the Benjamini-Hochberg procedure.
Functional profiling and comparisons
Functional profiles of the gut microbiota were predicted using the PICRUSt [Phylogenetic Investigation of Communities by Reconstruction of Unobserved States] software package. 26 PICRUSt predicts the [portion of the full] metagenome in environmental DNA samples from 16S rRNA gene data. With the predicted metagenome, Kyoto Encyclopedia of Genes and Genomes [KEGG] pathway functions were categorised at level 2 using the phylogenetic investigation of communities by reconstruction of unobserved states.
LDA Effect Size [LEfSe: Linear Discriminant Analysis Effect Size] was used to detect significant changes in relative abundance of predicted KEGG pathways between pre-IFX, post-IFX, and control. 27 LEfSe uses the non-parametric factorial Kruskal-Wallis test to detect features with prominently different abundances between the assigned classes, and then it performs LDA to estimate the effect size of each feature. In the present study, a significance α-value [on factorial Kruskal-Wallis test] of 0.01 and an effect size threshold [on the logarithmic LDA score] of 3.0 were used.
Results
Characteristics of faecal microbiota composition revealed gut microbial dysbiosis in paediatric CD
For characterising gut microbiota associated with paediatric CD, we recruited children with a well-established diagnosis of CD [n = 11, between the ages of 4 and 17 years with a mean of 11 years, Table 1] and healthy control subjects presenting no abdominal pain, diarrhoea, or inflammatory conditions [n = 16, between the ages of 4 and17 years with a mean of 12 Figure 1A] . Analysis of the beta diversity calculated on the Bray-Curtis dissimilarity, unweighted and weighted UniFrac distances [ Figure 1B ], revealed that faecal microbial community of pre-IFX samples apart from that of control.
Inter-group comparisons of taxonomic profiles revealed that samples from patients before IFX therapy exhibited alterations in the abundance of several taxa [ Figure 2A ; and Supplementary Figure S1 , available as Supplementary data at ECCO-JCC online]. A lower relative abundance of Bacteroidetes together with a higher abundance of Proteobacteria were observed in the pre-IFX samples compared with controls [phylum level, Supplementary  Figure 1 ], which agrees with previous research.
15-17 At the family level, Actinomycetaceae, Enterobacteriaceae, Enterococcaceae, Planococcaceae, and Streptococcaceae were more abundant in the pre-IFX samples, whereas Alcaligenaceae, Bifidobacteriaceae, Clostridiaceae, Desulfovibrionaceae, Ruminococcaceae, and Turicibacteraceae were significantly reduced compared with the healthy controls [family level, Supplementary Figure 1] . At the genus level, relative abundances of Actinomyces, Enterococcus, Klebsiella, Streptococcus, and Veillonella were relatively higher in the pre-IFX samples compared with the controls [ Figure 2A ]. In particular, the genus Enterococcus, which was undetectable in the healthy control subjects, was remarkably abundant in the CD patients before IFX therapy. It is noteworthy that most of the significantly reduced genera found in pre-IFX samples were short-chain fatty acid [SCFA]-producing taxa, including Anaerostipes, Blautia, Clostridium, Coprococcus, Faecalibacterium, Lachnospira, Odoribacter, Roseburia, Ruminococcus, and Sutterella, [28] [29] [30] [31] [32] [33] suggesting that SCFA production was diminished [ Figure 2A ].
We continued analysis by predicting the functional composition of the faecal microbiota using PICRUSt. 26 Functional inferences were made by matching taxonomic data to KEGG Orthology. 34 LEfSe was then used to explore the derived KEGG pathways that were differentially expressed in the three clinical groups. Different metabolic pathways were enriched in the faecal microbiota of healthy and CD patients [ Figure 3] . At KEGG pathway level 2, xenobiotics biodegradation and metabolism were the most abundant functions identified in the pre-IFX samples [ Figure 3A] . At KEGG pathway level 3, the faecal microbiome of the pre-IFX group was enriched in functional categories associated with transcriptors, phosphotransferase system, secretion system, transcription factors, and pathogenic Escherichia coli infection [ Figure 3B ]. In the samples of healthy controls, multiple functional pathways that were more highly represented were also involved in metabolism [six out of 10 at KEGG pathway level 2, Figure 3A ; six out 17 at KEGG pathway level 3, Figure 3B ]. Thus, the faecal microbiota of CD patients may use different metabolic pathways from those in controls.
In summary, paediatric CD patients exhibited distinct structure in their faecal microbiome community compared with the healthy controls: the reduced microbial diversity, diminished SCFA-producing bacteria, and overgrowth of opportunistic taxa constituted the characteristic gut microbial dysbiosis. Analysis of the KEGG pathways indicated dysfunction of intestinal microbiome in the paediatric CD patients; multiple metabolic pathways were downregulated.
IFX corrected gut microbial dysbiosis in paediatric CD patients, with therapeutic response associated with SCFA-producing bacteria
Following IFX treatment [herein after termed post-IFX-x, which indicates the samples were collected after x number of IFX infusions], both the richness and diversity of gut microbiota were improved in the paediatric CD patients [ Figure 1A ]. PCoA showed that the bacteria community in the post-IFX samples was close to the control group [ Figure 1B] , suggesting that the dissimilarity between CD cases and the healthy controls was reduced during IFX treatment.
Statistical analysis of bacterial taxa revealed that the faecal microbiota of the paediatric CD patients was shifted toward a healthy composition [ Figure 2 and Supplementary Figure 1] . Specifically, the relative abundances of Enterobacteriaceae, Enterococcaceae, Planococcaceae, and Streptococcaceae were reduced in paediatric CD patients during IFX therapy, whereas the families that were significantly less abundant in the pre-IFX samples were increased [family level, Supplementary Figure 1] . Regarding the SCFA-producing bacteria, the genera Blautia, Faecalibacterium, Odoribacter, and Sutterella were found elevated and maintained [with no significant difference compared with the abundances in the controls] during IFX therapy [ Figure 2A] ; Coprococcus, Lachnospira, Roseburia, and Ruminococcus were also increased in the CD patients by IFX, but their abundances were unstable [ Figure 2A ].
In the present study, all the patients treated with IFX have achieved remission; however, only some [n = 4] experienced sustained therapeutic response to IFX [ Table 1 ]. Thus, identifying gut microbial signatures that associated with response to IFX in CD may lead to better selection of patients for this therapy and/or potential ways to improve the patients' response. By comparing the faecal microbiota in patients with sustained response [SR; PCDAI ≤ 10 at each follow-up time point during therapy, Blautia, Faecalibacterium, Lachnospira and Roseburia, were elevated higher in SR post-IFX samples compared with the NSR counterparts [ Figure 2B ].
By investigating the functional profiles of gut microbiota during IFX treatment, no significant difference (log 10 [LDA] > 3.0) at the KEGG pathways was identified in the post-IFX samples compared with healthy controls, suggesting that the gut microbial function was greatly recovered in the CD patients.
Discussion
The alterations in the gut microbiota during IBD have been suggested as biomarkers for disease diagnosis, outcomes prediction, and treatment response. 35 A prolonged treatment with anti-TNF medications, such as IFX, is frequently advised for CD patients. However, a high relapse rate [42.6%] was obtained within 1 year after IFX withdrawal. 21 Assessing how the gut microbial community varies during therapeutic intervention may provide new insights into IFX treatment optimisation. In this study, we characterised the gut microbiota dysbiosis in paediatric CD patients as represented by a reduced biodiversity, together with specific taxonomic alterations in the faecal microbiome community. Although the number of individuals in this patient cohort was rather small, the characteristics of dysbiosis were still identified from the faecal samples. The increased abundance in Enterobacteriaceae and Veillonella, and decreased abundance in Blautia, Clostridium, Coprococcus, Faecalibacterium, Roseburia and Ruminococcus [within the families of Ruminococcaceae and Lachnospiraceae], agree with previous studies. 11, 36 Remarkably, the genus Enterococcus was highly enriched in the faecal samples of these Chinese paediatric CD patients before IFX treatment [ Figure 2A ]. The virulence and bacteriocinogenic potential of the genus Enterococcus has been established in many 16, [41] [42] [43] [44] [45] Consistent contractions in all of these clades may thus weaken the ability of CD patients to regulate inflammation and repair the epithelium. SCFA, such as acetate, butyrate, and propionate produced by microbial fermentation of non-digestible carbohydrates, are a primary source of energy for colonic epithelial cells and are highly involved in determining the gut environment, influencing gut transit, nutrient uptake, pH, and microbial balance within the intestine. 46 Importantly, SCFA exerts immunomodulatory and anti-inflammatory properties, mainly via mediating homeostasis of colonic regulatory T cell populations. [47] [48] [49] Additionally, the anti-inflammatory effect of SCFA may be also attributed to other mechanisms. For instance, secretion of metabolites by F. prausnitzii can block NF-κB activation and IL-8 production. 44 Hence, reduced SCFA-producing species may favour a shift towards an inflammation-promoting microbiome, thereby enhancing host inflammation and worsening the condition of CD.
IFX was the first anti-TNF drug approved for patients with CD. In the present study, seven [88%] enrolled paediatric CD patients received scheduled IFX maintenance treatment. Investigation of the stool samples collected at different time points during IFX treatment show that the gut microbiota structure of the paediatric CD patients was clearly modified and maintained stably during the treatment period [between 1 and 7 infusions]. Specifically, the CD-characterised dysbiosis was diminished, with an increase in biodiversity, a decrease in opportunistic bacteria, and a gain in several SCFA-producers [ Figure 2 ]. Nevertheless, not all SCFA-producing bacteria were expanded to the levels observed in the healthy controls, and some of them were unstable during therapy [e.g. Coprococcus, Lachnospira, Roseburia, and Ruminococcus], implying that the anti-inflammatory capacity of these patients were not fully recovered.
The metabolic activities of the gut microbiota contributed to the pathogenesis of CD, and were reflected in the genes encoded into their genomes. Using PICRUSt, we investigated functional perturbations in the faecal microbiome of CD patients before and during IFX therapy. Dysfunction, in particular downregulation of some metabolic capacities, was observed in the faecal microbiota of CD patients before IFX therapy [ Figure 3 ], suggesting that microbial function was significantly altered in gut flora of CD patients. During IFX therapy, the alterations of microbial functions of CD patients were greatly corrected [ Figure 3] .
Despite a high primary response rate [70-90%], 50 the longterm outcome of IFX-treated CD is still suboptimal, with the loss of response rate approximately 13% per patient-year and ~40% of patients losing response eventually. 51 Many patients with CD on IFX maintenance therapy have recurrent symptoms despite an initial clinical response, which was also observed in paediatric patients of the present study [NSR in Table 1 ]. IFX treatment is expensive and has associated toxicities, such as infectious complications. Thus identifying predictors of response to IFX would be of great benefit in the selection of patients for this treatment. Through a comparison of faecal microbiota between CD patients with an SR and a NSR, we observed that an SR was positively associated with an expansion of SCFA-producing bacteria, especially Blautia, Faecalibacterium, Lachnospira, and Roseburia. In a study of UC, 52 anti-TNF [infliximab and adalimumab] responders were shown to have a higher abundance of F. prausnitzii [in mucosal biopsies] than non-responders at baseline. In another study of CD, 21 F. prausnitzii represented a predictive factor for recurrence after IFX discontinuation. Thus, these studies suggest an important role of F. prausnitzii and/or SCFA production ability in influencing the outcome of IFX therapy for IBD. Due to the relatively small size of our cohort, it was difficult to discern any patterns that predict the response to IFX treatment.
Some efforts had been made to improve/sustain the outcome of IFX treatment, including combination with enteral nutrition. For example, it was suggested that concomitant enteral nutrition yielded SR to IFX in some patients with CD. 53 In fact, one of the benefits of enteral nutrition for CD patients was contribution to an increase in SCFA production. 54 Taken together, it is worthwhile to discover: i] if microbial composition before treatment can influence IFX treatment outcome; ii] if sustained capacity for producing SCFA is an essential condition for a sustained IFX response and prevention of relapse.
In conclusion, dysbiosis was identified from the faecal microbiota of paediatric CD patients, with characteristics including a reduced biodiversity, a gain in opportunistic bacteria, and a loss in SCFA-producing bacteria. The exclusive high abundance of genus Enterococcusin patients before IFX treatment implies its role oinCD pathogenesis and inflammation promotion. IFX treatment modulated the gut microbiota composition and functional capabilities of paediatric CD patients towards healthy status. However, multiple SCFA-producing taxa were not expanded sufficiently in CD patients, especially not in those with a non-sustained therapeutic response, indicating a potential influence of these bacteria on the outcome of IFX therapy.
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